HER2阳性乳腺癌靶向治疗药物Herceptin耐药机制的新进展  

New progress in Herceptin resistance mechanism of HER2 positive breast cancer targeted therapy

作　　者：李雨琴 黄剑 LI Yu-Qin;HUANG Jian(Center for Pathological Diagnosis and Research,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,China)

机构地区：[1]广东医科大学附属医院病理诊断与研究中心

出　　处：《生命科学》2020年第1期47-53,共7页Chinese Bulletin of Life Sciences

基　　金：国家自然科学基金项目(81572610);广东省“扬帆计划”引进紧缺拔尖人才(4YF16002G)。

摘　　要：人类表皮生长因子受体2 (human epidermal growth factor receptor 2, HER2)是乳腺癌中最重要的癌基因,在乳腺癌细胞的增殖、侵袭、转移和演化等过程中发挥着重要作用。Herceptin,一种人源化单克隆抗体,已广泛用于HER2阳性乳腺癌患者的临床治疗中,疗效显著,并已成为靶向治疗的一线药。然而,大部分HER2阳性的乳腺癌患者在接受Herceptin治疗一年后会发生耐药。现对Herceptin耐药的可能机制、恢复药物敏感性的可能方法及最新研究进展进行综述,以期为Herceptin耐药研究提供新的思路。Human epidermal growth factor receptor 2(HER2) is the most important oncogene in breast cancer and plays an important role in the proliferation, invasion, metastasis and evolution of breast cancer cells. Herceptin, a humanized monoclonal antibody, has been widely used in the clinical treatment of HER2-positive breast cancer patients. It has a remarkable effect and has become a first-line drug for targeted therapy. However, most HER2-positive breast cancer patients develop resistance after one year of Herceptin treatment. This article will review the possible mechanisms of Herceptin resistance, the possible methods of restoring drug susceptibility and the latest research progress, and provide new ideas for Herceptin resistance research.

关 键 词：乳腺癌 HER2 HERCEPTIN 耐药机制 

分 类 号：R36[医药卫生—病理学] R73[医药卫生—基础医学]